cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Adverum Biotechnologies Inc
2 own
6 watching
Current Price
$4.4
$0.07
(1.62%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
156.63M
52-Week High
52-Week High
29.70000
52-Week Low
52-Week Low
4.010000
Average Volume
Average Volume
0.2M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization156.63M
icon52-Week High29.70000
icon52-Week Low4.010000
iconAverage Volume0.2M
iconDividend Yield--
iconP/E Ratio--
What does the Adverum Biotechnologies Inc do?
Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, develops gene therapy product candidates to treat ocular and rare diseases. Its lead product candidate is ADVM-022, a single intravitreal injection gene therapy candidate used for the treatment of patients with chronic retinal, including wet age-related macular degeneration and diabetic macular edema. Adverum Biotechnologies, Inc. has license and collaboration agreements with University of California; Cornell University; GenSight; Lexeo; and Virovek. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was incorporated in 2006 and is headquartered in Redwood City, California.
Read More
How much money does Adverum Biotechnologies Inc make?
News & Events about Adverum Biotechnologies Inc.
Globe Newswire
1 year ago
Adverum has granted Ray Therapeutics a non-exclusive, royalty-bearing license for the use of Adverums proprietary intravitreal AAV.7m8 vector capsid together with RayTxs RTx-015 assetREDWOOD CITY, Calif., June 12, 2023 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-...
Globe Newswire
1 year ago
- Wet age-related macular degeneration (wet AMD) is a bilateral disease and incidence of neovascularization (nAMD) in the second eye is up to 42% in the first two to three years following diagnosis in the primary eye - - Staggered administration of Ixo-vec in non-human primates (NHPs) showed peak ...
Ticker Report
1 year ago
LADENBURG THALM/SH SH assumed coverage on shares of Adverum Biotechnologies (NASDAQ:ADVM Get Rating) in a research report report published on Tuesday , The Fly reports. The brokerage issued a buy rating and a $2.00 price objective on the biotechnology companys stock. Several other ...
Ticker Report
1 year ago
LADENBURG THALM/SH SH started coverage on shares of Adverum Biotechnologies (NASDAQ:ADVM Get Rating) in a research note released on Tuesday , The Fly reports. The firm issued a buy rating and a $2.00 price target on the biotechnology companys stock. A number of other research analysts...
Ticker Report
2years ago
Adverum Biotechnologies, Inc. (NASDAQ:ADVM Get Rating) was the target of a significant decline in short interest during the month of December. As of December 15th, there was short interest totalling 2,140,000 shares, a decline of 11.9% from the November 30th total of 2,430,000 shares. ...
Frequently Asked Questions
Frequently Asked Questions
What is Adverum Biotechnologies Inc share price today?
plus_minus_icon
Can Indians buy Adverum Biotechnologies Inc shares?
plus_minus_icon
How can I buy Adverum Biotechnologies Inc shares from India?
plus_minus_icon
Can Fractional shares of Adverum Biotechnologies Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Adverum Biotechnologies Inc stocks?
plus_minus_icon
What is today’s traded volume of Adverum Biotechnologies Inc?
plus_minus_icon
What is today’s market capitalisation of Adverum Biotechnologies Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Adverum Biotechnologies Inc?
plus_minus_icon
What percentage is Adverum Biotechnologies Inc down from its 52-Week High?
plus_minus_icon
What percentage is Adverum Biotechnologies Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$4.4
$0.07
(1.62%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Related Stocks
Sign up and dive into a whole new world of investing.
Join over 500,000 who have signed up and are using Stockal successfully already.
Related Stocks
Sign up and dive into a whole new world of investing.
Join over 500,000 who have signed up and are using Stockal successfully already.

              Borderless Softtech Pvt Ltd ("BSPL") licenses and offers the Stockal Platform to subscribers and users who are based in India and wish to make global transactions. Such subscribers and users may be offered annual or monthly subscription plans by BSPL and in such cases, BSPL acts as their service provider.

              Borderless Investing Inc., (“Borderless Investing”), the owner of the Stockal Platform, is not a broker-dealer nor an investment advisor and through its affiliate stockbroker Stockal Securities Pvt. Ltd., (SEBI INZ000301236), acting as the introducing entity has entered into a clearing agreement with DriveWealth LLC., to offer U.S. equities on the Stockal Platform. The Stockal Platform enables investments in a diverse set of global assets from a single account from anywhere in the world. As such, Borderless Investing makes no warranties or representations, express or implied, on products and services offered through its website/platform. It accepts no liability for any damages or losses, however, caused in connection with the use of related services.

              All investments involve risk and returns will fluctuate, are subject to market volatility and may cause losses. The material on this website/platform is provided solely for informational and educational purposes and shall not in any manner be considered a recommendation or endorsement of any strategy or investment, nor an offer to sell or a solicitation of an offer to buy securities, products or services nor advice. Borderless Investing makes no guarantee as to the currency, accuracy, or quality of information published and/or archived on this website/platform, nor will Borderless Investing accept any responsibility for other organizations, businesses, and private persons that provide information on this website/platform. All information on this website/platform regarding products and services provided by Borderless Investing is subject to change without notice. Reasonable efforts are taken to ensure the accuracy and integrity of all information provided here, but Borderless Investing is not responsible for misprints, out of date information, or errors. Any investment decision and/or strategy that investors make or employ, whether or not such decision or strategy derives from or relies upon material accessed or provided through this website/platform, is undertaken at the investor’s sole discretion and risk. Before making any investment decisions, investors should consult additional sources of information and/or their legal or tax advisor. PLEASE READ THIS FULL DISCLOSURE CAREFULLY BEFORE USING THIS SERVICE. BY USING THE SERVICE OR CLICKING AGREE YOU ARE AGREEING TO BE BOUND BY THESE DISCLOSURES AND ALL TERMS AND CONDITIONS ON THIS WEBSITE/PLATFORM.

              *DriveWealth LLC., a member of the Securities Investor Protection Corporation (SIPC), will serve as the custodian for your securities account. In the event that DriveWealth LLC., fails and is placed in liquidation under the Securities Investor Protection Act, securities in your brokerage account may be protected up to $500,000. For details, please see www.sipc.org.

              All brands and logos used on this website are the property of their respective owners.

              Get Started with as little as $1.00